OTC · Financial Statements

bioMérieux S.A. (BMXXY) Financial Statements

$7.60 OTC: BMXXY Market Cap $8.96B

bioMérieux S.A. most recently reported annual revenue of $4.1B, net profit of $382.0M. Revenue grew at an average annual rate of 5.5% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

bioMérieux S.A.: Revenue rose from $2.1B in 2016 to $4.1B in 2025, a change of +93.5% over 9 years; net profit was positive in all 10 reported years; operating margin moved from 11.5% to 17.1%, a shift of +5.6 percentage points; the most recent year shows net profit of $382.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$2.1B$2.3B$2.4B$2.7B$3.1B$3.4B$3.6B$3.7B$4.0B$4.1B
Operating Expenses$1.9B$2.0B$2.1B$2.3B$2.6B$2.6B$3.0B$3.2B$3.4B$3.4B
Operating Profit$242.0M$287.0M$318.0M$331.0M$551.0M$784.0M$587.0M$439.0M$589.0M$695.0M
Operating Margin11.5%12.5%13.1%12.4%17.7%23.2%16.4%11.9%14.8%17.1%
Other Income$-23.0M$6.0M$-25.0M$-23.0M$-28.0M$-10.0M$-7.0M$-2.0M$-9.0M$-169.0M
Interest$19.0M$16.0M$20.0M$22.0M$25.0M$9.0M$4.0M$4.0M$16.0M$16.0M
Depreciation$148.0M$168.0M$178.0M$182.0M$184.0M$192.0M$240.0M$289.0M$302.0M$307.0M
Profit Before Tax$238.0M$271.0M$296.0M$319.0M$524.0M$775.0M$581.0M$437.0M$579.0M$526.0M
Tax$24.6M$12.1M$13.9M$15.3M$23.2M$22.7M$24.1M$26.2M$26.6M$19.3M
Net Profit$179.0M$238.0M$257.0M$273.0M$404.0M$601.0M$452.0M$358.0M$432.0M$382.0M
EPS$0.15$0.20$0.22$0.23$0.34$0.51$0.38$0.30$0.36$0.32
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricJun '20Dec '20Jun '21Dec '21Jun '22Dec '22Jun '23Dec '23Jun '24Dec '24Jun '25Dec '25
Revenue$1.5B$1.6B$1.6B$1.8B$1.7B$1.9B$1.8B$1.9B$1.9B$2.1B$2.0B$2.0B
Operating Expenses$1.3B$1.3B$1.2B$1.4B$1.4B$1.7B$1.6B$1.7B$1.6B$1.8B$1.8B$1.8B
Operating Profit$225.0M$327.0M$346.0M$394.0M$266.0M$265.0M$187.0M$231.0M$288.0M$301.0M$209.0M$178.0M
Operating Margin15.2%19.9%21.9%21.9%16.0%13.7%10.6%12.1%15.2%14.5%10.2%8.8%
Interest$0$0$0$0$0$0$2.0M$2.0M$0$0$0$0
Profit Before Tax$207.0M$288.0M$346.0M$402.0M$278.0M$272.0M$194.0M$229.0M$283.0M$296.0M$213.0M$310.0M
Tax$16.8M$19.7M$20.0M$19.9M$18.6M$21.3M$28.6M$19.6M$24.2M$29.0M$24.7M$24.4M
Net Profit$173.0M$232.0M$277.0M$324.0M$228.0M$224.0M$162.0M$196.0M$215.0M$217.0M$161.0M$235.0M
EPS$0.15$0.20$0.23$0.27$0.19$0.19$0.14$0.16$0.18$0.18$0.14$0.20

Over the 10 years reported for bioMérieux S.A., borrowings increased from $453.0M in 2016 to $461.0M in 2025, cash stood at $570.0M in the latest year, shareholders' equity was $12.0M, current assets covered current liabilities 2.39 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$3.0B$3.0B$3.5B$3.8B$3.9B$4.6B$5.2B$5.3B$5.8B$5.6B
Current Assets$1.2B$1.3B$1.3B$1.4B$1.7B$2.2B$2.2B$2.2B$2.5B$2.5B
Cash$179.0M$238.0M$288.0M$275.0M$389.0M$804.0M$553.0M$352.0M$450.0M$570.0M
Inventory$410.0M$387.0M$425.0M$501.0M$542.0M$620.0M$737.0M$909.0M$1.0B$975.0M
Receivables$537.0M$513.0M$539.0M$589.0M$640.0M$666.0M$909.0M$729.0M$858.0M$1.0B
Fixed Assets$734.0M$711.0M$899.0M$1.0B$1.1B$1.2B$1.4B$1.5B$1.7B$1.7B
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$67.0M$148.0M$67.0M$42.0M$51.0M$62.0M$91.0M$206.0M$180.0M$129.0M
Other Assets$471.0M$443.0M$603.0M$653.0M$629.0M$670.0M$813.0M$699.0M$730.0M$727.0M
Total Liabilities$1.4B$1.3B$1.5B$1.5B$1.4B$1.4B$1.5B$1.5B$1.6B$1.5B
Current Liabilities$760.0M$652.0M$796.0M$1.2B$924.0M$956.0M$1.1B$1.1B$1.1B$1.1B
Borrowings$453.0M$468.0M$654.0M$592.0M$481.0M$463.0M$505.0M$519.0M$491.0M$461.0M
Other Liabilities$954.0M$785.0M$848.0M$935.0M$965.0M$979.0M$1.0B$988.0M$1.1B$1.0B
Equity$12.0M$12.0M$12.0M$12.0M$12.0M$12.0M$12.0M$12.0M$12.0M$12.0M
Reserves$1.6B$1.7B$1.9B$2.2B$2.4B$3.1B$3.6B$3.8B$4.2B$4.1B

For bioMérieux S.A., operating cash flow was positive in 10 of 10 reported years; free cash flow in the latest year was $435.0M; free cash flow was positive in 10 of 10 years; financing activities used $18.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$318.0M$341.0M$400.0M$408.0M$583.0M$825.0M$475.0M$445.0M$667.0M$757.0M
Investing Cash Flow$-477.0M$-375.0M$-634.0M$-578.0M$-543.0M$-597.0M$-815.0M$-827.0M$-706.0M$-766.0M
Financing Cash Flow$-46.0M$-12.0M$-22.0M$0$-18.0M$-17.0M$-157.0M$0$-38.0M$-18.0M
Net Cash Flow$42.0M$59.0M$51.0M$-13.0M$107.0M$414.0M$-259.0M$-195.0M$109.0M$173.0M
Free Cash Flow$85.0M$158.0M$173.0M$135.0M$305.0M$535.0M$188.0M$107.0M$322.0M$435.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-2.61
EV / EBITDA8.79
FCF Yield5.34%
Quick Ratio1.48
Interest Coverage24.58
Return 1Y-37.77%
Return 3Y-2.63%
Return 5Y—

bioMérieux S.A. (BMXXY) financials — frequently asked questions

What is bioMérieux S.A.'s annual revenue?

bioMérieux S.A. (BMXXY) reported annual revenue of $4.1B in its most recent fiscal year.

What is bioMérieux S.A.'s net profit?

bioMérieux S.A. (BMXXY) reported net profit of $382.0M in its most recent fiscal year.

What is BMXXY EV/EBITDA?

bioMérieux S.A.'s enterprise value to EBITDA (EV/EBITDA) ratio is 8.79.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
BMXXY Overview BMXXY Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.